Key Takeaways: How to Fix SEND Compliance Gaps in Mid-Sized Biotechs
- Mid-sized biotech R&D teams face unique SEND challenges because they often lack dedicated standards specialists yet run multiple concurrent studies.
- Internal workflow breakdowns such as fragmented data sources and manual transcription cause most SEND dataset errors before validation even begins.
- PointCross helps biotechs achieve 100% alignment between study reports and SEND datasets through automated reconciliation and traceability.
- Evolving CDISC versions and FDA requirement dates demand version-controlled metadata repositories rather than ad hoc spreadsheet tracking.
- Building SEND readiness into study design from the start eliminates the costly post-report conversion bottleneck that delays submissions.
What Is SEND and Why Does Compliance Matter for Biotechs?
The Standard for Exchange of Nonclinical Data (SEND) is the CDISC-endorsed format for organizing animal study data in FDA submissions. If your biotech submits nonclinical toxicology, carcinogenicity, or DART studies to CDER or CBER, SEND dataset compliance is mandatory for studies starting after March 15, 2023.
The FDA enforces SEND through automated gateway checks. A submission missing a required Trial Summary dataset (ts.xpt) or using an outdated Define-XML version can trigger a refuse-to-file action before a reviewer ever opens it. For mid-sized biotechs with limited regulatory bandwidth, this creates real business risk.
Why Do Internal SEND Workflows Break Down at Mid-Sized Biotechs?
Large pharmaceutical companies employ dedicated SEND teams with mature metadata repositories. Smaller biotechs outsource everything to CROs. Mid-sized biotechs sit in an uncomfortable middle ground: they run enough studies in-house to need internal SEND capability, but often lack the specialist headcount to build robust processes.
This creates predictable failure points. Data scientists inherit SEND deliverables from departing colleagues without documentation. Version control exists in email threads rather than repositories. Study directors approve reports without confirming the SEND dataset can regenerate published summary tables.
Fragmented Data Sources Create Reconciliation Risk
Nonclinical data originates across multiple systems. LIMS captures clinical pathology and in-life observations. Anatomic pathology systems record microscopic findings. Bioanalytical platforms generate pharmacokinetic data. Spreadsheets fill gaps for everything else.
Each system uses different structures and terminology. Mapping all of it into SEND domains while preserving the exact means, standard deviations, and incidence counts reported in your GLP study report demands rigorous cross-checking. When a SEND dataset cannot regenerate the summary tables in the final report, FDA reviewers notice.
Manual Transcription Introduces Errors
Many biotechs still rely on manual transcription to move data from source systems into Word-based study reports. Study directors spend hours copying values into templates. SEND teams then separately extract the same source data to build datasets. This duplicated effort adds weeks of lag time and introduces discrepancies between the report narrative and the submitted data.
How Do SENDIG Version Changes Affect Your Compliance Strategy?
SEND is not a static standard. CDISC publishes new implementation guides, the NCI-EVS releases quarterly controlled terminology updates, and FDA requirement dates shift accordingly. A CRO or biotech running studies across different start dates must track multiple SENDIG versions simultaneously.
As of mid-2026, SENDIG v3.1.1 applies to general toxicology and carcinogenicity studies starting after March 15, 2023. SENDIG-DART v1.1 covers embryo-fetal development studies. SENDIG-Genetox v1.0 brought in vivo micronucleus and comet assays into scope for studies starting March 15, 2025. Define-XML v2.1 is required for all SEND packages.
Controlled Terminology Updates Add Complexity
CDISC SEND Controlled Terminology is published quarterly. Each release adds new terms, modifies existing submission values, and retires others with a documented change log. A test code or finding term valid last quarter may be deprecated this quarter. Your Define-XML must reference the exact controlled terminology version used for each study.
For biotechs managing concurrent studies started under different SENDIG versions, this becomes a configuration-management challenge. Teams that bolt SEND on at the end of a study feel every terminology change as rework.
What Causes FDA Technical Rejections for SEND Submissions?
The FDA enforces Technical Rejection Criteria automatically at the electronic submission gateway. A submission that fails a high-severity validation check is rejected before scientific review begins. This automated rejection has been active since September 15, 2021.
Four high-severity validation rules apply: Rule 1734 (ts.xpt with study start date must be present), Rule 1735 (correct file tags for datasets and Define-XML), Rule 1736 (DM dataset and Define-XML in Module 4), and Rule 1789 (study files referenced in Study Tagging File). Rule 1734 is the single most common rejection reason for nonclinical submissions.
FDA Rejection Data Reveals Common Mistakes
According to FDA presentation data from 2023, 453 IND, NDA, and BLA nonclinical studies failed Rule 1734 between September 2021 and February 2023. Of those, 73% failed due to a missing ts.xpt file. Repeat-dose toxicology studies accounted for 71% of failures.
These are not exotic scientific problems. A misformatted ISO 8601 study start date, a missing Trial Summary dataset, or a study ID mismatch is enough to bounce an entire submission. Every rejection cycle adds weeks and damages sponsor relationships.
How Can You Achieve Full Traceability Between Study Reports and SEND Datasets?
A SEND dataset can pass validation and still be wrong. Conformance checks verify that data fits the standard’s structure and terminology. They do not verify that values match your audited GLP study report.
Reconciling the two requires regenerating 100% of the study report’s summary tabulations from the SEND dataset and checking every value, including categorical incidence counts in domains like CL, MA, and MI. Manual spot-checks scale poorly and miss systematic errors.
PointCross SEND-ASSURE Ensures Report Alignment
PointCross offers SEND-ASSURE, a quality-check service that treats the audited study report as the trusted reference. Rather than sampling, SEND-ASSURE checks the full dataset by attempting to regenerate every summary table. If the SEND data cannot reproduce the published means, standard deviations, and counts, the discrepancy is flagged for correction before submission.
This approach eliminates the reconciliation risk that comes from building the study report and SEND dataset separately. The PointCross team validates against all applicable CDISC Conformance Rules, FDA Business Rules, and PMDA requirements using eDataValidator.
What Is the nSDRG and Why Is It Difficult to Author?
The nonclinical Study Data Reviewer’s Guide is a PDF document that explains your SEND datasets to FDA reviewers. It describes study design, justifies any deviation from pure SEND such as custom domains, and lists the controlled terminology versions used. An incomplete or contradictory nSDRG is a common trigger for FDA information requests.
The challenge is internal consistency. The nSDRG must align perfectly with the datasets and the Define-XML. Any discrepancy creates questions that delay review.
Specialized Study Types Increase Documentation Burden
Carcinogenicity studies require a tumor.xpt companion file that sits outside core SEND and must be traced in the nSDRG. DART and juvenile studies introduce post-natal-day timing concepts that current SENDIG versions represent imperfectly. Immunotoxicity, neurobehavioral, and ophthalmology endpoints are not fully modeled until SEND 4.0 arrives, forcing custom domains today.
Each of these scenarios requires the nSDRG to carry more explanatory weight. Experienced scientific judgment determines how to document deviations without raising unnecessary red flags.
How Does Single Track Processing Accelerate SEND Readiness?
The traditional model treats SEND as a sequential, post-report step. Study directors finalize the GLP report, then a separate team converts source data to SEND weeks later. This sequencing creates a bottleneck and forces reconciliation after the fact.
A better model derives both the study report and the SEND dataset from a single versioned data model. PointCross calls this Single Track processing. When the Study Director signs off, the submission package is essentially complete rather than weeks away.
Faster Delivery Without Adding Headcount
Single Track processing compresses report-plus-SEND delivery by two weeks or more compared to traditional dual-track workflows. It eliminates the post-hoc reconciliation step that consumes specialist time and introduces errors.
Pairing this approach with interim study monitoring lets sponsors see standardized data as the study runs rather than waiting for data lock. Mid-sized biotechs gain the operational efficiency of large pharma without the headcount investment.
What Steps Should Mid-Sized Biotechs Take to Close Compliance Gaps?
Fixing SEND compliance gaps requires process changes, not just better tools. Start by designing for SEND from study initiation rather than retrofitting at the end. Define which SENDIG version applies based on your study start date and lock that decision into your study plan.
Centralize Metadata Management
Version control for controlled terminology and SENDIG versions should live in a dedicated metadata repository, not in spreadsheets or email threads. When CDISC publishes terminology updates, your repository absorbs the change once rather than per study.
Validate Early and Continuously
Run validation checks throughout study conduct, not just before submission. Catching structural errors early avoids last-minute rework. Use validation engines that stay current with FDA Business Rules and CDISC Conformance Rules.
Build Cross-Functional Accountability
SEND compliance is not solely a data management function. Study directors must understand that their narrative text creates expectations the SEND dataset must fulfill. Toxicologists should review nSDRG content for scientific accuracy. Regulatory affairs should track FDA Data Standards Catalog updates.
What Is Changing in SEND 4.0 and Future Standards?
SEND 4.0 is expected to add approximately eight new domains covering in vivo genetic toxicology, cell phenotyping, immunogenicity, ophthalmology, nervous system tests, skin tests, and pharmacokinetic inputs. The current CDISC target for publication is mid-2026, though the timeline has shifted before.
History shows a substantial lag between CDISC publication and FDA enforcement. Organizations that build flexible metadata repositories and automated transformation pipelines can absorb these changes without disruption. Those relying on manual processes will face rework cycles with each new requirement.
Dataset-JSON May Replace XPT Format
The FDA is evaluating CDISC’s Dataset-JSON format as a replacement for the longstanding SAS XPT transport files. A Federal Register Notice in early 2025 requested industry feedback. While XPT remains the current requirement, forward-thinking biotechs should monitor this transition and ensure their data infrastructure can support modern formats.
How Can PointCross Help Your Biotech Team?
PointCross brings SEND expertise across dataset preparation, 100% report-reconciled quality checks, FDA-rule-aware validation, and cross-study analytics. The team has processed over 1,500 studies and works with 5 of the top 15 pharma clients globally.
For mid-sized biotechs, PointCross offers firm fixed-price quotes with guaranteed turnaround times. Free no-commitment indicative quotes for SEND needs are available to help you plan budgets and timelines accurately.
FAQs about How to Fix SEND Compliance Gaps in Mid-Sized Biotechs
What is SEND compliance and why does it matter for mid-sized biotechs?
SEND compliance means submitting nonclinical study data in CDISC’s Standard for Exchange of Nonclinical Data format, along with Define-XML metadata and an nSDRG document. Mid-sized biotechs face particular challenges because they often lack dedicated standards teams. PointCross helps these organizations achieve submission readiness without building large internal capabilities.
Which nonclinical studies require SEND datasets?
Single-dose and repeat-dose general toxicology, carcinogenicity, cardiovascular and respiratory safety pharmacology, embryo-fetal development, and in vivo genetic toxicology studies require SEND when the study start date falls after the relevant FDA requirement date. Both GLP and non-GLP studies are in scope when the design qualifies.
What is the most common reason FDA rejects SEND submissions?
Validation rule 1734, which flags a missing or invalid Trial Summary dataset (ts.xpt), is the most common technical rejection reason. FDA data show 73% of nonclinical study failures between 2021 and 2023 resulted from a missing ts.xpt file. PointCross validation tools catch these structural errors before gateway submission.
How can biotechs ensure consistency between study reports and SEND datasets?
The best approach regenerates 100% of study report summary tabulations from the SEND dataset and verifies every value matches. PointCross SEND-ASSURE performs this full reconciliation rather than relying on manual spot-checks. This ensures the submitted data can reproduce all published means, standard deviations, and incidence counts.
What is Single Track processing for SEND?
Single Track processing generates both the study report and SEND dataset from a single versioned data model simultaneously. This eliminates the traditional 5-6 week lag between report completion and SEND delivery. PointCross Single Track processing delivers study report packages two weeks faster while ensuring 100% alignment between report and data.
How should biotechs prepare for SEND 4.0?
SEND 4.0 will add domains for immunogenicity, ophthalmology, nervous system tests, and other specialized endpoints. Organizations should build metadata repositories and transformation pipelines that can absorb new SENDIG versions without manual rework. PointCross XBIOM platform supports version-controlled standardization that adapts as requirements evolve.